Invokana medication is manufactured and marketed by Janssen pharmaceuticals in the U.S. and developed by a Japanese pharmaceutical company, Mitsubishi Tanabe Pharma Corporation. It was a first SGLT2 scientifically known as type 2 sodium-glucose co-transporter) inhibitor that provide treatment for Type 2 diabetes by working differently as compared to other ant diabetics. Manufacturers and marketers present this medication in market to provide cure for Type 2 diabetes that if not treated properly increase the risk for various serious problems such as high blood pressure, nerve damage, heart disease, gastro paresis, blindness, foot complications, kidney failure, stroke and etc. In last year May the U.S. Food and Drug Administration has issued a warning about the risk of ketoacidosis that may occur after taking the anti diabetic medication, Invokana. Diabetic ketoacidosis (DKA) is a serious condition that can lead to diabetic coma (passing out for a long time) or even death.
In December 7th 2016 an order was issued by the Judicial Panel for Multidistrict Litigation states that those lawsuits which claims that diabetes medications Invokana and Invokamet cause ketoacidosis, kidney damage, and other injuries were transferred to New Jersey District Court for consolidation. As per the order all the lawsuits from districts in Georgia, Illinois, Kentucky, Missouri, Louisiana, Minnesota, Virginia and West Virginia are consolidated to the New Jersey District Court before U.S. District Judge Brian R. Martinotti. Due to the consolidation of federal cases in New Jersey the number of Invokana lawsuits has been increasing steadily. As per a report by JPML on Dec. 15 there were 63 Invokana cases filed as part of the multidistrict litigation and according to a updated report released on January 17th by JPML the number of lawsuits rises to 100 this month and more cases are expected to be filed in the future.
Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals, are facing hundreds of Invokana lawsuits due to serious injury caused by Invokana. Plaintiffs claimed in their consolidation request that the drug’s manufacturer did nothing, rather than warn the public, Janssen Pharmaceuticals, a subsidiary of corporate giant Johnson & Johnson, actively defended its product and failed to provide adequate warnings and communications to the medical community and end line consumers of the increased risk of serious and life threatening medical complications associated with these drugs. On October 2015; FDA received reports of 101 confirmable cases of acute kidney injury, some requiring hospitalization and dialysis, with canagliflozin or dapagliflozin use. More than 100,000 people are affected with Kidney failure in the United States each year. The safety communications from the FDA didn’t stop J&J from pursuing an Invokana approval to treat Type 1 diabetes.
The FDA has taken measures to warn patients. But Invokana still remains on the market. The agency has to take action to protect consumers from dangerous medicines and ban these life threatening drugs from the market. If you or someone you love who was prescribed Invokana and then suffered from ketoacidosis, kidney failure, Heart Attack or Stroke may be eligible to file a personal injury lawsuit against the drug’s manufacturer. The Drugsclaim Lawyers and Attorneys are investigating claims that Invokana may be linked to kidney failure, cardiovascular complications and bone fractures. In filing personal injury lawsuits, injured patients seek compensation for medical expenses, lost work and pain and suffering, among other damages.